The combination of dalantercept plus axitinib (Inlyta) failed to significantly improve progression-free survival (PFS) in patients with advanced renal cell carcinoma (RCC) compared with placebo, according to results from the phase II DART trial.
Investigators reported no dose-limiting toxicities, grade 4/5 drug-related AEs, or serious bleeding events in the dose-escalation cohorts (n = 15). The most common (≥20%) drug-related treatment-emergent AEs included fatigue, diarrhea, peripheral edema, nausea, increased creatinine, epistaxis, pericardial effusion, and telangiectasia.
The DART Study: Results from the dose-escalation and expansion cohorts evaluating the combination of dalantercept plus axitinib in advanced renal cell carcinoma. Voss MH, Bhatt RS, Plimack ER, et al. Clin Cancer Res. [published online December 28, 2016] doi: 10.1158/1078-0432.CCR-16-2395.
... to read the full story